A Phase 2 interventional study of Bazedoxifene and Conjugated Estrogens in Risk Reduction and Breast Cancer, sponsored by University of Kansas Medical Center. Active, not recruiting at 6 sites in United States. Open to female participants aged 45 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Kansas Medical Center · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Risk Reduction Behavior with a site in United States — 10 open to participants now, 16 under way, none of them phase 3. Risk Reduction Behavior · United States.
Among the 153 studies in Risk Reduction Behavior with a site in United States, this one is the 81st largest by planned enrollment of the 140 interventional ones that give a count, is one of 13 that started in 2021, is one of 5 in phase 2, reaches primary completion later than 3 of the 15 other live ones, and was the 108th registered.
291 studies on the registry are indexed under Risk Reduction Behavior; 38 are open to participants now.
Browse Risk Reduction Behavior studies →10 of the 153 studies in Risk Reduction Behavior with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–44 · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 8–17
Uniformed Services University of the Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Uniformed Services University of the Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 16–17 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Risk Reduction Behavior studies recruiting now, 11 (39%) set no upper age limit and 11 (39%) stop at 75 or younger; 6 take children under 18; 16 take healthy volunteers.
This study: 45 Years to 64 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 3 · Phase 4 3
First in 1998; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 201 across 250 interventional studies indexed under Risk Reduction Behavior.
Median enrollment 169 across the 140 interventional studies, 377 across the 13 observational. Of the 123 that completed or were terminated, 33 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 153 have an industry lead sponsor. The 10 most frequent:
University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
University of Kansas Medical Center has 2 studies filed under Risk Reduction Behavior — fewer than ten, so there is no comparison to draw.
4 of the studies in Risk Reduction Behavior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06971978University of WashingtonStudy to Assess the Effectiveness of a Heat Risk Reduction Decision Support Platform and the Barriers and Facilitators of Its Implementation With 30 US Local Health Department Sites | 2026-12 |
| NCT06822387Colorado State UniversityHealth Without Barriers/Salud Sin Barreras- Northern Colorado | 2026-12-31 |
| NCT06067451Northwell HealthSMART GOALS for Youth With Prediabetes | 2027-02-27 |
| NCT06052943Colorado State UniversityHealth Without Barriers/Salud Sin Barreras | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 153 studies in Risk Reduction Behavior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine needle aspiration (RPFNA). Change in biomarkers will be compared between groups.
Phase IIB trial of 6 months of BZA 20 mg +CE 0.45 mg (subsequently designated as BZA+CE) vs a waitlist control. Trial is informed by prior results of a single arm trial that used Duavee® (combination of BZA+CE that is FDA-approved for relief of hot flashes). Since Duavee® is currently not available commercially, the two separate components are used instead. Breast imaging, benign breast tissue by RPFNA, and blood for biomarkers will be obtained at baseline and at 6 months using similar assessment techniques. The primary endpoint is the difference between the BZA+CE and control groups for absolute change from baseline to 6 months in the risk biomarker fibroglandular volume (FGV). Volpara® fully automated assessments overcome the interpretive variance inherent in subjective assessments. Additional endpoints include changes in benign breast epithelial immunolabeling for Ki-67, estrogen receptor alpha (ERα), progesterone receptor (PR), and anterior gradient-2 protein (AGR2); and systemic levels of bioavailable hormones, IGF-1, IGFBP3, and measures of insulin sensitivity. The modifying effects of baseline BMI, visceral adipose, and plasma BZA concentrations on markers will be studied.
Inclusion Criteria for Baseline Mammogram and RPFNA Women ages 45 - 60 or ages 61-64 if their last mammogram was described as heterogeneously or extremely dense.
Current vasomotor symptoms (hot-flashes, night sweats or both). These do not need to be frequent or severe but should occur at least once a week. Women who feel that they would likely need a supplement or be at high risk of withdrawal if they were randomized to waitlist because of vasomotor symptoms are not good candidates for this trial.
Women must be in one of the four menopausal status categories, as defined below.
Must have at least one ovary.
: ≤ 38 kg/m2
At least one breast without prior therapeutic radiation that can be assessed by Volpara® software.
Chemistry profile showing reasonably normal renal and hepatic function: creatinine \<2.0 mg/dL, \< 2.5 mg/dL, and albumin > 3.4 g/dL within the past 12 months.
Risk Factors/Level. Moderate risk of developing breast cancer based on having at least one of following:
Vaginal Hormones: Low dose vaginal hormones, such as Estring(®, Vagifem®, Imvexy®, or 0.5 gram or less of conjugated estrogen vaginal cream twice weekly or less often, for vaginal dryness and dyspareunia may be continued at the same dose.
Systemic Hormones: If previously on oral contraceptives or systemic hormone replacement such as pills, transdermal patches, oral troches, or injections, must be off for 8 weeks or more prior to baseline mammogram and RPFNA.
Exclusion Criteria for Screening
Conditions:
Medications
Inclusion Criteria for Randomization Study mammograms
RPFNA must be performed and specimen received at KUMC in good condition. RPFNA specimen must have ductal/lobular epithelial cells on Thinprep® slides; but there is no requirement for a specific cell number, value for Ki-67, or cytomorphology.
Blood must be drawn prior to randomization and sent to KUMC.
Complete Menopause specific quality of life questionnaire, information for hot flash score.
Willing to comply with study procedures.
Participants at KUMC: Dual energy x-ray absorptiometry (iDXA)
Pregnancy test for women \<age 55 with intact uterus
Exclusion Criteria for Randomization Intercurrent illness which makes potential participant unsuitable for study; Starting hormone replacement therapy (prescription pills, injections, patches) between mammogram/RPFNA and enrollment on study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing immediately.
Drug: Bazedoxifene and Conjugated Estrogens
No intervention for initial 6 months (wait list), then BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing 6 months after enrollment. Optional on the part of subject.
Drug: Bazedoxifene and Conjugated Estrogens
Drug pages: BazedoxifeneStudies of BazedoxifeneBazedoxifene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Conjugated estrogensStudies of Conjugated estrogensConjugated estrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
BZA (20 mg) plus CE (0.45 mg) taken together once daily
Also known as: BZA+CE
Change in FGV
Change in fibroglandular volume assessed on 3-D digital mammogram by Volpara software.
Time frame: baseline to 6 months
Change in proliferation
change in percent of breast epithelial cells staining positive for Ki-67 by immunocytochemistry
Time frame: baseline to 6 months
Change in blood hormones
Exploratory analysis of change in levels of hormones (estradiol, progesterone, testosterone, sex hormone binding globulin, etc.) assessed by ELISA or RIA methods at baseline and at 6 months.
Time frame: baseline to 6 months
change in gene expression
Exploratory analysis of changes and patterns of change in levels of mRNA assessed by qRT-PCR
Time frame: baselne to 6 months
Plan to share: No
Started Dec 2021 (actual). Primary completion is estimated for Oct 2026, 58 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bazedoxifene · Conjugated estrogens
University of Kansas Medical Center →